Mouse Anti-MAGEA3 Recombinant Antibody (CBT4531) (V2LY-0625-LY1658)

Eakins, R. A., Chobrutskiy, A., Teer, J. K., Patel, D. N., Hsiang, M., Huda, T. I., ... & Chobrutskiy, B. I. (2022). Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity. Molecular immunology, 150, 58-66.

Craig, A. J., Garcia-Lezana, T., Ruiz de Galarreta, M., Villacorta-Martin, C., Kozlova, E. G., Martins-Filho, S. N., ... & Villanueva, A. (2021). Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS genetics, 17(6), e1009589.

Martin, A. D., Wang, X., Sandberg, M. L., Negri, K. R., Wu, M. L., Warshaviak, D. T., ... & Kamb, A. (2021). Re-examination of MAGE-A3 as a T-cell therapeutic target. Journal of Immunotherapy (Hagerstown, Md.: 1997), 44(3), 95.

Das, B., & Senapati, S. (2021). Immunological and functional aspects of MAGEA3 cancer/testis antigen. Advances in Protein Chemistry and Structural Biology, 125, 121-147.

Chen, Y., Zhao, H., Li, H., Feng, X., Tang, H., Zhang, J., ... & Qiu, C. (2020). LINC01234/MicroRNA-31-5p/MAGEA3 axis mediates the proliferation and chemoresistance of hepatocellular carcinoma cells. Molecular therapy. Nucleic acids, 19, 168.

Gao, X., Li, Q., Chen, G., He, H., & Ma, Y. (2020). MAGEA3 promotes proliferation and suppresses apoptosis in cervical cancer cells by inhibiting the KAP1/p53 signaling pathway. American Journal of Translational Research, 12(7), 3596.

Das, B., & Senapati, S. (2019). Functional and mechanistic studies reveal MAGEA3 as a pro-survival factor in pancreatic cancer cells. Journal of Experimental & Clinical Cancer Research, 38(1), 1-18.

Pol, J. G., Acuna, S. A., Yadollahi, B., Tang, N., Stephenson, K. B., Atherton, M. J., ... & McCart, J. A. (2019). Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology, 8(1), e1512329.

Conley, A. P., Wang, W. L., Livingston, J. A., Ravi, V., Tsai, J. W., Ali, A., ... & Roszik, J. (2019). MAGE-A3 is a clinically relevant target in undifferentiated pleomorphic sarcoma/myxofibrosarcoma. Cancers, 11(5), 677.

Ravichandran, R., Kodali, K., Peng, J., & Potts, P. R. (2019). Regulation of MAGE‐A3/6 by the CRL 4‐DCAF 12 ubiquitin ligase and nutrient availability. EMBO reports, 20(7), e47352.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols